{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:50:42Z","timestamp":1761871842335,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clml.2021.08.014","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T03:02:36Z","timestamp":1631156556000},"page":"e116-e123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Gal","family":"Sharvit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Heering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Zlotnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drorit","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-3524","authenticated-orcid":false,"given":"Jonathan","family":"Canaani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.08.014_bib0001","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.blre.2018.03.006","article-title":"Time to repeal and replace response criteria for acute myeloid leukemia?","volume":"32","author":"Bloomfield","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2021.08.014_bib0002","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","article-title":"End points to establish the efficacy of new agents in the treatment of acute leukemia","volume":"109","author":"Appelbaum","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2018.02.002","article-title":"Interpretation of clinical endpoints in trials of acute myeloid leukemia","volume":"68","author":"Medeiros","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.08.014_bib0004","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0005","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.08.014_bib0007","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.08.014_bib0008","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1200\/JCO.2008.20.6490","article-title":"Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10","volume":"27","author":"Mandelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0009","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1200\/JCO.2017.72.8618","article-title":"Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0010","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0011","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","article-title":"A randomized study of high-dose cytarabine in induction in acute myeloid leukemia","volume":"87","author":"Bishop","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0012","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2013.51.8571","article-title":"High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial","volume":"32","author":"Willemze","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0014","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0015","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood-2016-10-740613","article-title":"Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML","volume":"129","author":"Lowenberg","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0016","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN Guidelines insights: acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2021.08.014_bib0017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties","volume":"107","author":"Wheatley","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.08.014_bib0019","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cncr.25263","article-title":"Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group","volume":"116","author":"Rowe","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.08.014_bib0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2016.148825","article-title":"An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation","volume":"101","author":"Ferguson","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.014_bib0021","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjh.12178","article-title":"Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy","volume":"160","author":"Ling","year":"2013","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.clml.2021.08.014_bib0022","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.18632\/oncotarget.27618","article-title":"Reassessing the role of high dose cytarabine and mitoxantrone in relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Canaani","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.08.014_bib0023","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0024","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0025","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined eastern cooperative oncology group, southwest oncology group, and M. D. anderson cancer center study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.08.014_bib0026","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0027","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.08.014_bib0028","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3324\/haematol.2011.040592","article-title":"Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD","volume":"96","author":"de Jonge","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.014_bib0029","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1182\/blood.V99.10.3517","article-title":"A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup","volume":"99","author":"Nguyen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","article-title":"Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance","volume":"127","author":"Grimwade","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.014_bib0031","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2016.48","article-title":"Prediction of CR following a second course of '7+3\u2032 in patients with newly diagnosed acute myeloid leukemia not in CR after a first course","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:48Z","timestamp":1761871128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021020176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2152265021020176"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}